J Obes Metab Syndr.
2020 Jun;29(2):99-109. 10.7570/jomes20010.
Current Long-Term Pharmacotherapies for the Management of Obesity
- Kim BY1
- Kang SM2
- Kang JH3
- Kim KK4
- Kim B5
- Kim SJ6
- Kim YH7
- Kim JH8
- Kim JH9
- Nam GE7
- Park JY10
- Son JW11
- Shin HJ12
- Oh TJ13
- Lee H14
- Jeon EJ15
- Chung S16
- Hong YH17
- Kim CH
18 - Committee of Clinical Practice Guidelines
- Korean Society for the Study of Obesity (KSSO)
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
- 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Sun Medical Center, Daejeon, Korea
- 3Department of Family Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea
- 4Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- 5Department of Family Practice and Community Health, Ajou University Medical Center, Suwon, Korea
- 6Department of Psychiatry, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea
- 7Department of Family Medicine, Korea University College of Medicine, Seoul, Korea
- 8Department of Family Medicine, Eulji Hospital, Eulji University School of Medicine, Seoul, Korea
- 9Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- 10Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea
- 11Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea
- 12Department of Pediatrics, National Medical Center, Seoul, Korea
- 13Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- 14Central St’ Mary’s Clinic Internal Medicine, Seoul, Korea
- 15Division of Endocrinology and Metabolism, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
- 16Department of Pediatrics, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
- 17Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
- 18Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea
- KMID: 2503838
- DOI: http://doi.org/10.7570/jomes20010
Abstract
- Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.
